Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
combination drug |
| gptkbp:activeIngredient |
gptkb:liraglutide
gptkb:insulin_degludec |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
A10AE56
|
| gptkbp:brand |
gptkb:Xultophy
|
| gptkbp:combinationRatio |
100 units insulin degludec/3.6 mg liraglutide per mL
|
| gptkbp:contraindication |
type 1 diabetes
hypersensitivity to ingredients |
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:insulin_degludec/liraglutide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xultophy
|
| gptkbp:indication |
improving glycemic control
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:marketedAs |
gptkb:Novo_Nordisk
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
nausea diarrhea weight gain |
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:insulin
|
| gptkbp:bfsLayer |
6
|